{"id":15113,"date":"2026-06-18T09:05:58","date_gmt":"2026-06-18T07:05:58","guid":{"rendered":"https:\/\/q-finity.de\/news-2-2\/"},"modified":"2026-07-17T12:51:15","modified_gmt":"2026-07-17T10:51:15","slug":"news-2","status":"publish","type":"page","link":"https:\/\/q-finity.de\/en\/news-2\/","title":{"rendered":"News"},"content":{"rendered":"\n
<\/div>
Meet Qfinity<\/a><\/span>

BPD Biopharmaceutical Bioprocess Development Summit with QFINITY | August 6-7, 2026<\/span><\/a><\/h2><\/div><\/header><\/span>
\"BPD<\/a><\/div>

We are glad to be at the 9th BPD Biopharmaceutical Bioprocess Development Summit in Shanghai!<\/p>\n

The summit runs August 6-7, 2026 in Shanghai – China’s benchmark event for biopharmaceutical process development, from research to commercial manufacturing. Since 2017 it has connected the entire CMC value chain; the 2025 edition drew more than 5,500 attendees and over 160 speakers. The AI FOR PHARMA Conference 2026 runs alongside it.<\/p>\n

QFINITY on stage<\/h2>\n

Oliver Herrmann (QFINITY) and Martin Heitmann (MH Consulting & Advisory) are pleased to speak at both conferences on August 6: at the BPD Summit itself on the shift in EU GMP regulation, and at the parallel AI FOR PHARMA Conference on how adaptive AI only becomes GMP-ready under control.<\/p>\n

Shifting the EU GMP Regulatory Paradigm – Annex 11 and Annex 22 Drafts<\/h3>\n

Oliver Herrmann<\/strong> (QFINITY) and Martin Heitmann<\/strong> (MH Consulting & Advisory)<\/p>\n

“Global Expansion & Globalization” track. For companies expanding into European markets, the regulatory ground is shifting: the revised EU GMP Annex 11<\/a> and the new Annex 22 draft reshape how computerized systems – and, increasingly, AI – are assessed in GxP environments. The talk maps out what quality, IT, and regulatory teams need to prepare for.<\/p>\n

Adaptive AI Without Control is Not GMP – From Potential to Controlled Biopharma<\/h3>\n

Digital Compliance Architecture for Trustworthy Adaptive AI-Enabled Systems from Process<\/a> Development to GxP Manufacturing<\/em><\/p>\n

Oliver Herrmann<\/strong> (QFINITY) and Martin Heitmann<\/strong> (MH Consulting & Advisory)<\/p>\n

AI FOR PHARMA Conference. Adaptive AI systems change their behavior as new data comes in – exactly what makes them powerful and hard to keep in check. Without robust control, that potential never reaches GMP. The talk outlines a digital compliance architecture that keeps adaptive, AI-enabled systems trustworthy and verifiable, from process development through to GxP manufacturing.<\/p>\n

Meet us in Shanghai – we look forward to connecting in person.<\/p>\n<\/div><\/span>